New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

Treatment with a cold atmospheric plasma reduced the recurrence rate of melanoma tumours after surgery by roughly 50% ...

Lovey presented to the clinic lethargic, with inappetence but consuming plenty of water, and a bulge on her abdomen when ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...

Interdisciplinary collaboration is key to reducing the risk for osteonecrosis of the jaw and improving patient care.

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Imunon (IMNN) announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health Organization’s cancer agency has found.

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...